Skip to main content

Table 2 Adjusted odd ratios a (OR) for in situ breast cancer by tertile levels and on a continuous log 2 scale of circulating prolactin

From: Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study

  

Tertiles

 

Log 2

  
 

1

2

3

Odds ratio (95% CI)

P trend b

P het c

All women

      

Ca/Co

89/101

94/104

124/102

   

OR

Ref.

0.98 (0.65, 1.49)

1.37 (0.87, 2.16)

1.35 (1.04, 1.76)

0.03

 

Premenopausal

      

Ca/Co

27/29

19/28

40/29

   

OR

Ref.

0.63 (0.25, 1.58)

1.49 (0.59, 3.74)

1.30 (0.80, 2.10)

0.28

 

Postmenopausal (all)

      

Ca/Co

65/72

69/75

87/74

  

0.98

OR

Ref.

1.00 (0.61, 1.63)

1.31 (0.77, 2.22)

1.38 (1.00, 1.91)

0.05

 

Postmenopausal non-HT users

      

Ca/Co

50/51

39/49

50/39

   

OR

Ref.

0.84 (0.44, 1.6)

1.27 (0.65, 2.47)

1.20 (0.82, 1.76)

0.35

 

Postmenopausal HT users

      

Ca/Co

15/21

30/26

37/35

  

0.20

OR

Ref.

1.63 (0.70, 3.81)

1.62 (0.64, 4.09)

1.77 (0.98, 3.21)

0.06

 
  1. aAdjusted for parity (nulliparous, parous, or missing data), smoking status (current, never, previous, or missing data) and body mass index (continuous scale); blinear trends for odds ratio estimates over a continuous scale of prolactin levels; cstatistical tests for heterogeneity were based on the likelihood-ratio test, comparing the model fit for logistic regression models with and without a corresponding interaction term. Ca/Co, Case/Control; Ref., reference; HT, hormone therapy.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us